Overcoming multi‐resistant leishmania treatment by nanoencapsulation of potent antimicrobials

Leishmaniasis corresponds to a group of neglected tropical diseases caused by flagellated protozoa belonging to the Leishmania genus. This widely spread illness is found in over 90 countries in tropical and sub‐tropical regions and also in southern Europe. As parasites exclusively infect highly phag...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemical technology and biotechnology (1986) 2021-08, Vol.96 (8), p.2123-2140
Main Authors: Oliveira, Simone SC, Ferreira, Carine S, Branquinha, Marta H, Santos, André LS, Chaud, Marco V, Jain, Sona, Cardoso, Juliana C, Kovačević, Anđelka B, Souto, Eliana B, Severino, Patrícia
Format: Article
Language:English
Subjects:
Antimicrobial agents
Bioavailability
Clinical trials
Drug therapy
Health services
Leishmaniasis
Macrophages
Nanoparticles
nanovaccines
Parasite resistance
Phagocytes
Phagocytosis
Protozoa
Side effects
targeted delivery
Tropical diseases
Tropical environment
Tropical environments
Vector-borne diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Leishmaniasis corresponds to a group of neglected tropical diseases caused by flagellated protozoa belonging to the Leishmania genus. This widely spread illness is found in over 90 countries in tropical and sub‐tropical regions and also in southern Europe. As parasites exclusively infect highly phagocytic cells (macrophages), this aspect can be exploited for targeted delivery making use of nanoparticles. Drug‐loaded nanoparticles have been proposed for improving the bioavailability of classical drugs commonly in use as standard leishmania therapy, to overcome parasitic resistance and side effects and to improve treatment efficacy. Infected macrophages are expected to recognize drug‐loaded nanoparticles, which undergo phagocytosis releasing the drug inside the macrophages. This approach can further be exploited for the development of nanovaccines. This paper provides an overview of the current disease status worldwide, its classical pharmacological treatments and how these can be improved by the use of featured nanoparticles specifically tailored for such a complex disease. Several types of nanoparticles have been proposed while others have already reached clinical trials. © 2020 Society of Chemical Industry
ISSN:0268-2575
1097-4660
DOI:10.1002/jctb.6633